PD-1/PD-L1抑制剂对肺鳞状细胞癌患者调节性T细胞及其亚型的影响  

Effects of PD-1/PD-L1 Inhibitor on Regulatory T Cells and Their Subtypes in Patients with Lung Squamous Cell Carcinoma

作　　者：李廷慧[1] 刘芳[2] 任志鹏[2] 侯晓彬[2] LI Ting-hui;LIU Fang;REN Zhi-peng;HOU Xiao-bin(Department of dermatology,The 8th Medical Center,Chinese PLA General Hospital,Beijing,100091,China;Department of thoracic surgery,The First Medical Center,Chinese PLA General Hospital,Beijing,100853,China)

机构地区：[1]解放军总医院第八医学中心皮肤科,北京100091 [2]解放军总医院第一医学中心胸外科,北京100853

出　　处：《现代生物医学进展》2022年第14期2678-2681,2699,共5页Progress in Modern Biomedicine

基　　金：全军"十二五"应用基础研究面上项目(CWS11J105)。

摘　　要：目的:探讨PD-1/PD-L1抑制剂对肺鳞状细胞癌(鳞癌)患者调节性T细胞(Regulatory T cell,Treg细胞)及其亚型的影响。方法:2019年1月至2020年12月来我院就诊的肺鳞癌初诊患者纳入本项研究;患者均接受Nivolumab治疗,根据治疗效果不同,将患者分为缓解组(n=20)和无效组(n=20);流式细胞术检测外周血总Treg细胞、PD-1+Treg细胞、CD150+Treg细胞、CTLA-4+Treg细胞、LAG-3+Treg细胞的比例。结果:缓解组外周血总Treg细胞、CTLA-4+Treg细胞和LAG-3+Treg细胞的比例分别为4.052±0.231%、1.616±0.099%和0.328±0.021%,无效组的比例分别为5.532±0.395%、3.277±0.224%和0.857±0.108%,差异均具有显著的统计学意义(t=3.239,P=0.009;t=6.776,P<0.001;t=4.807,P<0.001);缓解组外周血PD-1+Treg细胞和CD150+Treg细胞的比例分别为0.195±0.016%和1.530±0.113%,无效组的比例分别为0.203±0.018%和1.787±0.157%,差异均不具有统计学意义(t=0.318,P=0.757;t=1.329,P=0.214)。结论:PD-1/PD-L1抑制剂治疗无效的肺鳞癌患者外周血总Treg细胞、CTLA-4+Treg细胞和LAG-3+Treg细胞的比例均显著升高。Objective:To investigate the effects of PD-1/PD-L1 inhibitor on regulatory T cells(Treg cells)and their subtypes in patients with lung squamous cell carcinoma.Methods:Newly diagnosed patients with lung squamous cell carcinoma admitted to our hospital from January 2019 to December 2020 were included in this study.All patients received Nivolumab,and were divided into remission group(n=20)and ineffective group(n=20)according to different therapeutic effects.Flow cytometry was used to detect the proportion of total Treg cells,PD-1+Treg cells,CD150+Treg cells,CTLA-4+Treg cells,and LAG-3+Treg cells in peripheral blood.Results:The proportions of total Treg cells,CTLA-4+Treg cells and LAG-3+Treg cells in the remission group were 4.052±0.231%,1.616±0.099%and 0.328±0.021%,respectively,and those in the ineffective group were 5.532±0.395%,3.277±0.224%and 0.857±0.108%,respectively,the differences were statistically significant(t=3.239,P=0.009;t=6.776,P<0.001;t=4.807,P<0.001).The proportions of PD-1+Treg cells and CD150+Treg cells in the remission group were 0.195±0.016%and 1.530±0.113%,respectively,and those in the ineffective group were 0.203±0.018%and 1.787±0.157%,respectively,with no statistically significant differences(t=0.318,P=0.757;t=1.329,P=0.214).Conclusion:The proportions of total Treg cells,CTLA-4+Treg cells and LAG-3+Treg cells in peripheral blood of patients with lung squamous cell carcinoma who did not respond to PD-1/PD-L1 inhibitors were significantly increased.

关 键 词：肺癌 鳞癌 调节性T细胞 免疫治疗 PD-1 

分 类 号：R734.2[医药卫生—肿瘤]